Jing He

发表

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.

T. Wilson, N. Harbeck, V. Diéras, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.